TG Therapeutics' (TGTX) new multiple sclerosis drug, Briumvi, experienced a "solid jump" in March sales, according to a report that sent TGTX stock flying on Monday.
In the second month following Briumvi's launch, the MS treatment generated $3.3 million in sales, Cantor Fitzgerald analyst Prakhar Agrawal wrote in a note to clients Sunday. That compares with $500,000 in sales during February, he said, citing Symphony Health data.
Overall, first-quarter sales were about $4 million, above forecasts for $2.5 million to $3.8 million, Agrawal said. TGTX stock analysts polled by FactSet predict $3.8 million in sales.
"We estimate that Briumvi is likely to meet/exceed the current first-quarter consensus revenue estimates," Agrawal said.
https://www.investors.com/news/technology/tgtx-stock-rockets-on-solid-jump-in-ms-drug-sales/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.